Reviva Pharmaceuticals Q3 2026 Earnings Date & Estimates

Reviva Pharmaceuticals (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system, inflammatory and cardiometabolic disorders. The company’s lead product candidate is brilaroxazine, formerly known as RP5063, a novel serotonin-dopamine activity modulator being developed for psychiatric and neurological conditions.

Brilaroxazine has been evaluated in clinical studies for schizophrenia and has also been investigated for other potential indications, including bipolar disorder, major depressive disorder, dementia-related behavioral symptoms and pulmonary arterial hypertension. Reviva’s development strategy is based on the compound’s activity across multiple serotonin and dopamine receptors, although its safety and effectiveness for these uses remain subject to regulatory review and further clinical evaluation.

Reviva was founded by Laxminarayan Bhat, Ph.D., who serves as the company’s president and chief executive officer. The company is headquartered in Cupertino, California, and conducts its research and clinical-development activities through collaborations and trials involving patients in the United States and other international markets.